Association of PTP1B gene polymorphism with obesity in Chinese children

Juan Mo1, Jing Wu, Zhixiang Sun

  • 1Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.

Insights

The protein tyrosine phosphatase 1B (PTP1B) gene Pro303Pro polymorphism is linked to childhood obesity in Chinese children, potentially impacting lipid metabolism. The IVS6+G82A polymorphism showed no significant association with childhood obesity.

Area of Science:

  • Genetics
  • Pediatrics
  • Metabolic Disorders

Background:

  • Childhood obesity is a growing global health concern with complex genetic and environmental factors.
  • Protein tyrosine phosphatase 1B (PTP1B) plays a crucial role in insulin signaling and energy homeostasis.
  • Genetic variations in the PTP1B gene may influence susceptibility to obesity.

Purpose of the Study:

  • To examine the distribution of PTP1B gene IVS6+G82A and Pro303Pro polymorphisms in Chinese children.
  • To determine the association between these PTP1B polymorphisms and the pathogenesis of childhood obesity.

Main Methods:

  • Genotyping of IVS6+G82A and Pro303Pro polymorphisms using PCR-RFLP in 147 obese and 118 healthy Chinese children.
  • Assessment of various anthropometric (WC, WHR, %BF) and metabolic parameters (SBP, DBP, FPG, TG, TC, HDL-C, LDL-C, FINS, HOMA-IR, leptin).

Main Results:

  • Significant differences in allele frequencies for the Pro303Pro polymorphism were observed between obese and healthy children.
  • The Pro303Pro polymorphism was associated with increased body mass index, waist circumference, triglycerides, and LDL-C in obese children.
  • No significant association was found for the IVS6+G82A polymorphism with childhood obesity or related clinical characteristics.

Conclusions:

  • The PTP1B gene Pro303Pro polymorphism may contribute to the pathogenesis of obesity in Chinese children.
  • This polymorphism might influence lipid metabolism in obese children, highlighting its potential role in metabolic dysregulation.
Abstract

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...